Search Result

Results for "

cerebral cortex

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (4) Amino Acid Derivatives (1) Amyloid-β (1) Apoptosis (2) ATP Synthase (2) Calcium Channel (2) Cholecystokinin Receptor (3) Cholinesterase (ChE) (4) Dopamine Receptor (2) Dopamine Transporter (1) Endogenous Metabolite (6) Fungal (1) GABA Receptor (6) Histamine Receptor (3) Histone Methyltransferase (1) iGluR (2) mAChR (3) mGluR (1) Monoamine Transporter (1) Neurokinin Receptor (1) NO Synthase (5) Potassium Channel (2) Reactive Oxygen Species (2) Reference Standards (3) Thyroid Hormone Receptor (1) TMV (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (5) Endocrinology (2) Infection (2) Inflammation/Immunology (10) Metabolic Disease (8) Neurological Disease (38)

By Targets:

5-HT Receptor (4)

Adrenergic Receptor (4)

Amino Acid Derivatives (1)

Amyloid-β (1)

Apoptosis (2)

ATP Synthase (2)

Calcium Channel (2)

Cholecystokinin Receptor (3)

Cholinesterase (ChE) (4)

Dopamine Receptor (2)

Dopamine Transporter (1)

Endogenous Metabolite (6)

Fungal (1)

GABA Receptor (6)

Histamine Receptor (3)

Histone Methyltransferase (1)

iGluR (2)

mAChR (3)

mGluR (1)

Monoamine Transporter (1)

Neurokinin Receptor (1)

NO Synthase (5)

Potassium Channel (2)

Reactive Oxygen Species (2)

Reference Standards (3)

Thyroid Hormone Receptor (1)

TMV (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (5)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (10)

Metabolic Disease (8)

Neurological Disease (38)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-121186

Bevantolol hydrochloride	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Neurological Disease Metabolic Disease
Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-101333

CPPG (RS)-CPPG	mGluR	Neurological Disease
CPPG ((RS)-CPPG) is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC₅₀=2.2 nM) over group II (IC₅₀=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors .

HY-107563

ROS 234	Histamine Receptor	Inflammation/Immunology
ROS 234 is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 diaplays poor central access .

HY-107563A

ROS 234 dioxalate	Histamine Receptor	Inflammation/Immunology
ROS 234 dioxalate is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 dioxalate diaplays poor central access .

HY-121186R

Bevantolol (hydrochloride) (Standard)	Adrenergic Receptor Calcium Channel	Neurological Disease Metabolic Disease
Bevantolol (hydrochloride) (Standard) is the analytical standard of Bevantolol (hydrochloride). This product is intended for research and analytical applications. Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-P1588

Scyliorhinin II	Neurokinin Receptor	Neurological Disease Endocrinology
Scyliorhinin II is a selective neurokinin-3 receptor agonist, with a K_i of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

HY-116738

Trimecaine	Others	Neurological Disease
Trimecaine, a local neural blockade agent, has a strong depressant effect on the cerebral cortex and the ascending reticular formation of the brain stem .

HY-103114

AT1015 hydrochloride	5-HT Receptor	Cardiovascular Disease Neurological Disease
AT1015 hydrochloride is a potent antagonist of 5-HT₂ receptor, with the pK_i of 7.94. AT1015 inhibits vasoconstriction and blocks platelet aggregation .

HY-136800

Posatirelin	Thyroid Hormone Receptor	Endocrinology
Posatirelin, a TRH analog, increases monoamine metabolites in the cerebral cortex, nucleus accumbens, and striatum, and possibly exerts CNS activating effects through a modification of several neurotransmitter systems .

HY-100481

RP 72540 RPR101048	Cholecystokinin Receptor	Neurological Disease
RP 72540 is a selective CCK-B receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .

HY-130325

α-Guanidinoglutaric acid	NO Synthase	Neurological Disease
α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .

HY-W203728

L-β-Imidazolelactic acid	Amino Acid Derivatives	Neurological Disease
L-β-Imidazolelactic acid is a histidine derivative and an oxidizing agent that can trigger antioxidant effects in the brain cortex of rats .

HY-101324

MK-212 CPP	5-HT Receptor	Neurological Disease
MK-212 (CPP) is a centrally acting 5-HT_1C/5-HT₂ agonist. MK-212 can stimulate phosphoinositide hydrolysis in cerebral cortex .

HY-101324A

MK-212 monohydrochloride CPP monohydrochloride	5-HT Receptor	Neurological Disease
MK-212 (CPP) monohydrochloride is a centrally acting 5-HT_1C/5-HT₂ agonist. MK-212 monohydrochloride can stimulate phosphoinositide hydrolysis in cerebral cortex .

HY-N11911

Verazine (-)-Verazine	Fungal	Infection Neurological Disease
Verazine ((-)-Verazine) is an anti-Fungal Agent that can be found in the dried roots and rhizoma of Veratrum maackii Regel. Verazine causes DNA damage in the cerebellum and cerebral cortex of mice in a dose-dependent manner. Verazine can be used in the study of fungal infections and neurological diseases .

HY-U00033

Iomazenil	Endogenous Metabolite	Neurological Disease
Iomazenil is a benzodiazepine receptor antagonist with partial inverse agonist activity. Iomazenil can assess the binding potential of central benzodiazepine receptors in the cerebral cortex and may reflect neuronal function in viable tissue. Iomazenil use is associated with improved cognitive function in adult patients with ischemic cerebral pathology after indirect revascularization surgery. Iomazenil demonstrated restoration of benzodiazepine receptor binding potential in the affected hemisphere after surgery on brain SPECT imaging .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-N12249

7-Deoxy-trans-dihydronarciclasine	Amyloid-β TMV	Infection Neurological Disease Inflammation/Immunology
7-Deoxy-trans-dihydronarciclasine, an alkaloid, is a tobacco mosaic virus (TMV) inhibitor (IC₅₀: 1.80 μM). 7-Deoxy-trans-dihydronarciclasine is an anti-neuroinflammatory agent. 7-Deoxy-trans-dihydronarciclasine decreases the Aβ and APP levels in the cerebral cortex of Tg2576 mice .

HY-B1715

Oxiracetam ISF2522	GABA Receptor NO Synthase	Neurological Disease Inflammation/Immunology
Oxiracetam (ISF2522) is an orally active and a BBB-penetrable cyclic derivative of γ-aminobutyric acid (GABA). Oxiracetam reaches the hippocampus and cerebral cortex in high concentrations. Oxiracetam can promote cognitive function and regulate inflammatory response, with powerful neuroprotective effects. Oxiracetam can be used in the study of central nervous system diseases .

HY-117839

PD-135666	Cholecystokinin Receptor	Neurological Disease
PD-135666 is a dipeptide inhibitor of cholecystokinin B (CCK B) receptors, binding to CCK B receptors in mouse cerebral cortex with IC50 of 0.1 nM. Its enantiomer, PD-140548, preferentially binds to CCK A receptors with IC50 of 2.8 nM in rat pancreas. PD-135666 exhibits anxiolytic effects in animal models .

HY-116062

JNJ-7925476 hydrochloride	Monoamine Transporter Dopamine Transporter Adrenergic Receptor	Others
JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.

HY-18730

1400W W1400	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-114724

HSR-609	Histamine Receptor	Inflammation/Immunology
HSR-609 is an orally active amphoteric antiallergic agent. HSR-609 has a high affinity for histamine H1-receptor in the guinea pig cerebral cortex. HSR-609 inhibits allergic airway hyperresponsiveness to Acetylcholine. HSR-609 shows poor ability to penetrate into the CNS in mice and guinea pigs .

HY-105115

Abecarnil ZK 112119	GABA Receptor	Neurological Disease
Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABA_A receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC₅₀ of 0.82 nM. Abecarnil can be used for epilepsy research .

HY-113149

Argininosuccinic acid	Endogenous Metabolite Reactive Oxygen Species	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-113149A

Argininosuccinic acid disodium	Endogenous Metabolite Reactive Oxygen Species	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-111066

JNJ-37822681	Dopamine Receptor	Others
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.

HY-101324AR

MK-212 monohydrochloride (Standard) CPP monohydrochloride (Standard)	Reference Standards 5-HT Receptor	Neurological Disease
MK-212 (monohydrochloride) (Standard) is the analytical standard of MK-212 (monohydrochloride). This product is intended for research and analytical applications. MK-212 (CPP) monohydrochloride is a centrally acting 5-HT1C/5-HT2 agonist. MK-212 monohydrochloride can stimulate phosphoinositide hydrolysis in cerebral cortex .

HY-B1715R

Oxiracetam (Standard) ISF2522 (Standard)	Reference Standards GABA Receptor NO Synthase	Neurological Disease Inflammation/Immunology
Oxiracetam (Standard) is the analytical standard of Oxiracetam. This product is intended for research and analytical applications. Oxiracetam (ISF2522) is an orally active and a BBB-penetrable cyclic derivative of γ-aminobutyric acid (GABA). Oxiracetam reaches the hippocampus and cerebral cortex in high concentrations. Oxiracetam can promote cognitive function and regulate inflammatory response, with powerful neuroprotective effects. Oxiracetam can be used in the study of central nervous system diseases .

HY-17550

Sunifiram DM-235	iGluR	Neurological Disease
Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-18731

1400W Dihydrochloride 15+ Cited Publications	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-19651B

Zanapezil fumarate TAK-147 fumarate	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) fumarate is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil fumarate shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil fumarate shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil fumarate can be used for the research of early stages of Alzheimer's disease (AD) .

HY-19651A

Zanapezil TAK-147	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil can be used for the research of early stages of Alzheimer's disease (AD) .

HY-113126

3-Hydroxyisobutyric acid	Endogenous Metabolite ATP Synthase	Neurological Disease Metabolic Disease
3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-113126A

3-Hydroxyisobutyric acid sodium	Endogenous Metabolite ATP Synthase	Neurological Disease Metabolic Disease
3-Hydroxyisobutyric acid sodium is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid sodium is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid sodium can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid sodium are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-W116433

SK609	Dopamine Receptor	Neurological Disease
SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .

HY-19651

Zanapezil free base TAK-147 free base	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) free base is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil free base shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil free base shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil free base can be used for the research of early stages of Alzheimer's disease (AD) .

HY-17550R

Sunifiram (Standard)	iGluR	Neurological Disease
Sunifiram (Standard) is the analytical standard of Sunifiram. This product is intended for research and analytical applications. Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-126862

AQ-RA 721	mAChR	Others
AQ-RA 721 is a muscarinic receptor antagonist with differential affinity for the m4 and M2 sites, which can be used to characterize muscarinic receptor subtypes. Other muscarinic receptor antagonists have differential affinity for the M1 (rat cerebral cortex), M2 (rat heart), M3 (rat submandibular gland), m4 (receptor expressed in Chinese hamster ovary cells transfected with CHO), and guinea pig uterine smooth muscle at the muscarinic binding site .

HY-100991

FG 7142 ZK 39106; LSU-65	GABA Receptor	Neurological Disease
FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (K_i=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the α1 subunit (EC₅₀= 137 nM). FG 7142 (ZK 39106; LSU-65) can increase tyrosine hydroxylation and cause upregulation of β-adrenoceptors in mouse cerebral cortex .

HY-B0267A

Oxybutynin chloride	mAChR Potassium Channel	Neurological Disease Cancer
Oxybutynin chloride is an oral active and competitive mAChR antagonist with K_is of 14.3 and 5.55 nM for specific [ ³H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC₅₀ value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB) . Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-118275

FK960	Cholinesterase (ChE)	Neurological Disease
FK960 is a potential anti-dementia agent that reverses the reduction in cerebral blood flow (rCBF) caused by sensory stimulation by enhancing cholinergic neurotransmission. In macaque experiments, physostigmine (AChE inhibitor; HY-N6608) was able to completely eliminate the rCBF in the sensory cortex increased by vibrotactile stimulation. FK960 (1-1000 μg/kg) can restore the eliminated rCBF response, and the action time can last for 1 hour. However, FK960 cannot restore the rCBF response eliminated by HA-966 (NMDA modulator; HY-100822), indicating that its function is not dependent on non-glutamatergic neurotransmission.

HY-100991R

FG 7142 (Standard) ZK 39106 (Standard); LSU-65 (Standard)	Reference Standards GABA Receptor	Neurological Disease
FG 7142 (Standard) is the analytical standard of FG 7142. This product is intended for research and analytical applications. FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (Ki=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the α1 subunit (EC50= 137 nM). FG 7142 (ZK 39106; LSU-65) can increase tyrosine hydroxylation and cause upregulation of?β-adrenoceptors in mouse cerebral cortex .

HY-B0267AR

Oxybutynin chloride (Standard)	mAChR Potassium Channel	Neurological Disease
Oxybutynin (chloride) (Standard) is the analytical standard of Oxybutynin (chloride). This product is intended for research and analytical applications. Oxybutynin chloride is an oral active and competitive mAChR antagonist with K_is of 14.3 and 5.55 nM for specific [ ³H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC₅₀ value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB) . Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-136693

L-654284	Adrenergic Receptor	Neurological Disease
L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows K_i values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a K_i of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system .

HY-116062A

JNJ-7925476	Histone Methyltransferase	Neurological Disease
JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .

HY-B2167R

Docosahexaenoic acid (Standard)	Endogenous Metabolite	Neurological Disease Cancer
Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC₅₀ for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .

Cat. No.	Product Name	Type